Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Published: 15 November 2022
Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids.
Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.
Touchlight’s enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity and is being deployed across genetic medicine applications including mRNA, AAV, lentivirus, genome editing and DNA vaccines. doggybone DNA is amplified in vitro, avoiding the constraints of using cells for DNA amplification, thus also enabling applications such as the production of high-diversity DNA libraries.
“Today’s announcement is another example of the power and breadth of application of the doggybone DNA platform. We’re delighted that the platform is being utilised to contribute to the advancement of novel gene therapies for diseases of high unmet medical need.”
Karen Fallen, CEO of Touchlight
Financial terms are not disclosed.
About Touchlight
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation.
With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.
For more information please contact:
Karen Fallen, Chief Executive Officer
Verna McErlane, Chief Commercial Officer
E: info@touchlight.com
T: +44 20 8481 9200
Get all the latest updates
No spam. Just interesting articles, and exclusive updates in your inbox every week.
